0RDB Stock Chart & Stats
€2.99
-€0.05(-1.64%)
At close: 4:00 PM EDT
€2.99
-€0.05(-1.64%)
Day’s Range― - ―
52-Week Range€2.57 - €4.00
Previous CloseN/A
Volume3.89K
Average Volume (3M)22.58K
Market Cap
€236.04M
Enterprise Value€230.85
Total Cash (Recent Filing)€22.12M
Total Debt (Recent Filing)€7.10M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Oct 22, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding84,332,150
10 Day Avg. Volume17,750
30 Day Avg. Volume22,582
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.28Price Target Upside177.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.1
Revenue Forecast (FY)€6.56M
Bulls Say, Bears Say
Bulls Say
Niche Epigenetics FocusOryzon's focused expertise in epigenetics creates a durable competitive niche with high scientific barriers to entry. Specialized small-molecule programs in oncology and CNS increase the chance of differentiated assets, making the company an attractive partner for licensing and late-stage collaborators over multi-year development cycles.
Supportive Balance Sheet, Low LeverageRelatively low debt and increasing equity provide financial flexibility to fund multi-year clinical programs and to absorb R&D volatility. Improved leverage reduces near-term insolvency risk and supports the ability to pursue partnerships or staged financing rather than emergency dilution during lengthy development timelines.
Licensing And Collaboration Business ModelA licensing/collaboration model aligns with clinical-stage biotech economics: upfront, milestone and royalty potential and partner cost-sharing can offset R&D expense. Structurally this reduces commercialization burden and provides non-recurring but material funding avenues that can extend runway and validate programs.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the company cannot self-fund development and must rely on financing or partner deals. Over 2–6 months this structural cash burn pressures capital management, raises dilution risk, and constrains ability to escalate multiple clinical programs simultaneously without external funding.
Volatile And Irregular RevenueIrregular, non-recurring revenue undermines predictable funding of operations and makes multi-period planning difficult. Dependence on milestone or one-off payments rather than product sales increases execution risk and can delay program timelines if partner payments or deals fail to materialize.
No Profitability; Negative Returns On EquityContinued losses and negative ROE indicate capital is not producing shareholder returns and highlight long timelines to commercialization. This structural lack of profitability raises the bar for future funding events and implies that investors expect binary clinical or partnership outcomes to realize value.
Oryzon Genomics SA News
0RDB FAQ
What was Oryzon Genomics SA’s price range in the past 12 months?
Oryzon Genomics SA lowest share price was €2.57 and its highest was €4.00 in the past 12 months.
What is Oryzon Genomics SA’s market cap?
Oryzon Genomics SA’s market cap is €236.04M.
When is Oryzon Genomics SA’s upcoming earnings report date?
Oryzon Genomics SA’s upcoming earnings report date is Oct 22, 2026 which is in 74 days.
How were Oryzon Genomics SA’s earnings last quarter?
Oryzon Genomics SA released its earnings results on Jul 27, 2026. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.056 by €0.056.
Is Oryzon Genomics SA overvalued?
According to Wall Street analysts Oryzon Genomics SA’s price is currently Undervalued.
Does Oryzon Genomics SA pay dividends?
Oryzon Genomics SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Oryzon Genomics SA dividends here
What is Oryzon Genomics SA’s EPS estimate?
Oryzon Genomics SA’s EPS estimate is -0.07.
How many shares outstanding does Oryzon Genomics SA have?
Oryzon Genomics SA has 84,332,150 shares outstanding.
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Oryzon Genomics SA reported an EPS of €0 in its last earnings report, beating expectations of -€0.056. Following the earnings report the stock price went up 0.775%.
Which hedge fund is a major shareholder of Oryzon Genomics SA?
Currently, no hedge funds are holding shares in GB:0RDB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
0RDB Stock 12 Month Forecast
Average Price Target
€8.28
▲(177.07% Upside)